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Kristina Buder1,2*†, Constantin Lapa3†, Michael C Kreissl3,4, Andreas Schirbel3, Ken Herrmann3, Alexander Schnack5,
Eva-Bettina Bröcker1, Matthias Goebeler1, Andreas K Buck3 and Jürgen C Becker1,6Abstract
Background: Merkel cell carcinoma (MCC) is a rare cutaneous neoplasm with increasing incidence, aggressive
behavior and poor prognosis. Somatostatin receptors (SSTR) are expressed in MCC and represent a potential target
for both imaging and treatment.
Methods: To non-invasively assess SSTR expression in MCC using PET and the radiotracers [68Ga]DOTA-D-Phe1-
Tyr3-octreotide (DOTATOC) or -octreotate (DOTATATE) as surrogate for tumor burden. In 24 patients with histologically
proven MCC SSTR-PET was performed and compared to results of computed tomography (CT).
Results: SSTR-PET detected primary and metastatic MCC lesions. On a patient-based analysis, sensitivity of SSTR-PET
was 73% for nodal metastases, 100% for bone, and 67% for soft-tissue metastases, respectively. Notably, brain
metastases were initially detected by SSTR-PET in 2 patients, whereas liver and lung metastases were diagnosed
exclusively by CT. SSTR-PET showed concordance to CT results in 20 out of 24 patients. Four patients (17%) were
up-staged due to SSTR-PET and patient management was changed in 3 patients (13%).
Conclusion: SSTR-PET showed high sensitivity for imaging bone, soft tissue and brain metastases, and
particularly in combination with CT had a significant impact on clinical stage and patient management.
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tomographyBackground
Merkel cell carcinoma (MCC) is a rare, highly aggres-
sive, viral associated cutaneous neoplasm with neuroen-
docrine characteristics [1,2]. Indeed, it is characterized
by expression of neuroendocrine markers including so-
matostatin receptors (SSTR) [3,4]. Five-year survival rates
are as low as 66% for stage I, 51% for stage II, 39% and
18% for stage III and IV, respectively [5]. While a stan-
dardized staging system has been introduced with the 7th
edition of the AJCC staging manual [6,7], the definite sta-
ging algorithm for MCC remains to be established.
Current imaging procedures for patients with clinical
stage I/II disease include ultrasonography of regional* Correspondence: Buder_K@ukw.de
†Equal contributors
1Department of Dermatology, Venereology and Allergology, University
Hospital Würzburg, Josef-Schneider-Strasse 2, 97080 Würzburg, Germany
2Comprehensive Cancer Center Mainfranken, University Hospital Würzburg,
Josef-Schneider-Strasse 6, 97080 Würzburg, Germany
Full list of author information is available at the end of the article
© 2014 Buder et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.lymph nodes and the abdomen as well as a chest X-ray. A
sentinel lymph node biopsy (SLNB) is recommended for
all patients with no evidence of lymph node or distant me-
tastasis [8-11]. Contrast-enhanced computed tomography
(CT) is generally performed in patients with clinical stage
III/IV disease. Functional or molecular imaging modalities
such as 18 F-fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET) are increasingly used [12-17].
In analogy to neuroendocrine tumors (NET), SSTR ex-
pression may be used for staging [18]. 68Ga-labeled
1,4,7,10-tetraazacyclo-dodecane-N,N’,N”,N”-tetraaceticacid
D-Phe1-Tyr3-octreotide (68Ga-DOTATOC) and Tyr3-
octreotate (68Ga-DOTATATE) are somatostatin analogs
with high affinity to SSTR subtype 2 suitable for PET im-
aging, thereby offering superior spatial resolution [19].
Radiotracer uptake has been shown to correlate with
expression of SSTR 2 in NET and MCC [3,20,21].
SSTR-PET is more sensitive and accurate for tumor
detection than respective scintigraphic techniques [22].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to conventional imaging and FDG-PET in selected pa-
tients with MCC [23,24].
The aim of this study was to assess the impact of non-
invasive characterization of SSTR expression in MCC on
tumor staging, as compared to conventional staging by
CT and to explore its suitability as molecular target for
treatment of metastatic MCC.Methods
Patients
In 24 patients with histologically confirmed MCC, SSTR-
PET was performed. In a sub-cohort of 8 patients, repeti-
tive imaging was performed. The cohort included 16 male
and 8 female patients with a mean age of 68 years at in-
clusion (range 44–81). At the initial diagnosis, 6 pa-
tients had stage I disease, 5 patients were stage II, 10
patients were stage III and 3 patients were stage IV.
Two patients had a history of secondary malignancy in
complete remission. The median follow-up was 36 months
(range 18–57 months).
Due to the retrospective nature of our study, the re-
quirement for approval has been waived by the local
ethics committee of the University of Würzburg. Since
2009, the German federal law accepts the use of the ra-
diotracer 68Ga-DOTATATE under conditions of the
pharmaceutical law. Before that time point, the use of 68Ga-
DOTATATE was approved on a compassionate use base.
Nevertheless, in all of our patients, informed consent was
obtained prior to the imaging procedure.Study design
In this retrospective study, imaging studies of consecu-
tive patients with MCC examined between 05/2008 and
09/2011 were analyzed. SSTR-PET was performed in the
clinical routine on a compassionate use basis; informed
consent for the imaging procedures was obtained. It is a
retrospective analysis of single institutional data. Pa-
tient’s consent was obtained for publication of illustra-
tions including photos. CT of the thorax and abdomen
served as reference. SSTR-PET and CT data were ac-
quired within a mean interval of 12.5 days (range, 0–45).
In between, no surgery or systemic treatment was per-
formed. Head-neck MRI was performed if clinically in-
dicated. In 2010, an integrated PET/CT scanner was
introduced, enabling combined acquisition of PET and
CT data in 5 patients. In all patients, SSTR-PET and
CT data were documented as separate files, enabling
separate evaluation of PET and CT data.
Eight patients were re-staged by SSTR-PET after first-line
chemotherapy with liposomal doxorubicin or cisplatin-
based polychemotherapy.Somatostatin receptor PET
68Ga-DOTATOC/68Ga-DOTATATE was prepared using
a modification of the method described by Breeman
et al. [25] using a radiotracer synthesis module (Scintomics,
Fürstenfeldbruck, Germany). PET-scans were acquired
using a Siemens PET scanner (ECAT Exact 47, Siemens
Health Care, Erlangen, Germany). Acquisition started
30–45 minutes after intravenous injection of 68Ga-
DOTATOC (116 ± 46 MBq).
SSTR-PET/CT was performed on a dedicated scanner
(Siemens Biograph mCT 64, Siemens, Knoxville, USA)
40–60 min after injection of 68Ga-DOTATATE (122 ±
52 MBq).
Standardized uptake values (SUV) were calculated by
assigning spherical volumes of interest of 1.5 cm diameter
including foci of increased tracer uptake. In addition,
mean and maximum SUV values (SUVmax, SUVmean) were
calculated. A 1.5 cm spherical volume of interest was
drawn also to the center of the right lobe of the liver to
determine the SUVmean liver as reference for background
activity.
CT
Spiral CT of the chest and abdomen was performed
using a 16-slice multi-detector CT (Siemens Sensation
16, Siemens Healthcare) and intravenous contrast. If
clinically indicated the head, neck or lower extremities
were also included. In two stage I patients SPECT-CT
images were obtained during SLN detection. In one
stage I patient MRI was performed instead of CT.
Image interpretation and data analysis
All images were reviewed by two experienced nuclear
medicine physicians (C.L. and M.C.K.) and an experi-
enced radiologist (Al.S.), who were blinded to clinical
data. Analyses were performed on a patient and on a le-
sion basis. Lesion-based analysis was restricted to a max-
imum of 10 lesions per organ.
Results
Staging results of SSTR-PET and CT; patient-based
analysis
SSTR-PET was able to detect MCC lesions in all patients
with primary and/or metastatic disease with mild to
moderate tracer uptake. Concordance of CT and SSTR-
PET was observed in 20 of 24 patients (83%) in a patient-
based analysis; change of management due to SSTR-PET
occurred in 4/24 (17%) patients (Table 1). On a patient
basis, CT and SSTR-PET were concordant regarding over-
all tumor stage in all but one patient.
Three patients received SSTR-PET when the primary
tumor was present. Patient 3 had a T1 tumor, patient 15
an infiltrating T4 tumor (Figure 1) and patient 22 a T2
Table 1 Tumor stage of MCC patients, as assessed by
SSTR-PET and CT
No. SSTR-PET CT Up-staging by
SSTR-PET
Change of the therapeutic
management due to
SSTR-PET
1 IA* IA* No -
2 IA* IA* No -
3 IA IA No -
4 IA* IA* No -
5 IA* IA* No -
6 IA* IA* No Parotid surgery
(Warthin tumor)
7 IIIA* IIIA* No -
8 IIIB IIIB No -
9 IIIB IIIB No -
10 IIIB IIIB No -
11 IIIB IIIB* No -
12 IIIB* IIIB* No -
13 IIIB* IIIB* No -
14 IV IV No Bisphosphonate Tx
(bone mets)
15 IIIB IIC Yes Lymph node exstirpation
(positive)
16 IV IV Yes -
17 IV IV No Bisphosphonate Tx
(bone mets)
18 IV IV No -
19 IV IV No -
20 IV IV Yes -
21 IV IV No -
22 IV IV Yes -
23 IV IV No Bisphosphonate
Tx (bone mets)
24 IV IV No -
Clinical stage as indicated by SSTR-PET and CT. Asterisks (*) indicate patients
free of disease. Upstaging by SSTR-PET as compared to conventional imaging.
Change of management due to SSTR-PET was seen in 5 patients.
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primary tumors showed focally increased tracer uptake.
When compared to CT, lymph node metastases were
correctly identified by SSTR-PET in 8 of 11 patients (sensi-
tivity 73%; Table 2A). One patient was correctly up-staged
to stage IIIB (pN1b) by SSTR-PET but not by CT. In 6/6
patients with clinical stage I disease both SSTR-PET and
CT indicated N0 disease. SLNB was negative in these 6 pa-
tients, confirming absence of nodal involvement.
SSTR-PET correctly detected distant metastatic disease
in 10/10 patients. However, there were clinically significant
organ-specific differences in the number of metastatic sites
as compared to CT (Table 2A, Figure 2). Patient-based
analysis for different metastatic sites revealed 5 patientswith bone metastases by SSTR-PET versus 2 patients iden-
tified by CT (Table 2A). Soft-tissue metastases were de-
tected by SSTR-PET with a sensitivity of 67% (2/3); liver
and lung metastases diagnosed by CT were not detected
by SSTR-PET (liver 0/5, lung 0/2). Pleural metastases were
detected by SSTR-PET in 1 out of 2 patients (Table 2A).
Skin metastases were frequently located outside the field-
of-view of the CT scan. Hence, a direct comparison was
not feasible. Nevertheless, cutaneous metastases were visu-
alized by SSTR-PET in 6 of 8 patients with clinical diagno-
sis of cutaneous metastases; metastases <5 mm were not
detected. Interestingly, several cutaneous metastases did
not show increased tracer uptake despite a size >15 mm
indicating a reduced sensitivity of SSTR-PET for detection
of cutaneous metastases from MCC.
Diagnostic accuracy of SSTR-PET and CT: lesion-based
analysis
Detailed results are given in Table 2B. SSTR-PET de-
tected 62 lymph node metastases as compared to 105 le-
sions detected by CT (sensitivity, 59%). SSTR-PET revealed
focal tracer uptake in all bone and soft tissue lesions de-
tected by CT (sensitivity 100%); moreover, it indicated 15
additional osseous metastases without any correlate at cor-
responding CT.
SSTR-PET did not show any focal tracer uptake in the
liver and the lungs. Inhomogeneity of tracer uptake in
liver tissue was noticed but no focal lesions were de-
tected. SSTR-PET detected a single histology-confirmed
metastatic lesion in the parotid gland, which was not
seen by CT. Another parotid lesion was detected by both
SSTR-PET and CT but turned out as benign lesion after
histological work-up (Warthin tumor).
Discordant findings at SSTR-PET and CT
Patient 11 with stage IIIB disease presented with 2 lymph
nodes suspected to be metastases by CT while SSTR-PET
did not reveal focal tracer uptake. Complete lymph node
dissection revealed MCC metastases up to 5 mm in 2 out
of 9 nodes. In patient 15 it was contrariwise: CT returned
stage IIC disease (N0) whereas SSTR-PET indicated stage
IIIB (N1b) (Figure 1); targeted lymph node extirpation
confirmed N1a disease. Though, SSTR-PET did not
visualize N1b disease detected by CT in one stage IV pa-
tient (no. 22). In addition, 3 patients (no. 9, 17, and 20)
were found to have subcutaneous in-transit metastases
correctly identified by SSTR-PET but not by CT (no. 9, 17
outside field-of-view of the CT scan).
Change of therapeutic management according to SSTR-PET
Patient-specific changes of management due to SSTR-
PET results are listed in Table 1. Changes were observed
in 3/24 patients (13%): detection of bone metastases re-
sulted in treatment with bisphosphonates. Moreover,
Figure 1 Primary MCC and lymph node metastasis visualized by SSTR-PET. A female patient (no. 15) presented with a primary MCC on her
left cheek (A), which was visualized by both SSTR-PET (B) and CT (C). Additionally, SSTR-PET revealed increased tracer uptake (D) in a non-enlarged
lymph node (E). After resection, a 7 x 5 mm lymph node metastasis was histologically confirmed.
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local radiotherapy was excluded from treatment options.
Furthermore, change of management could have also
been possible in a fourth patient. SSTR-PET positivity of
the sentinel lymph node indicated a complete lymph
node dissection, but unremarkable morphologic imaging
by CT and ultrasound made this lesion doubtful prompt-
ing a targeted extirpation instead. Since histologic
workup confirmed a metastasis a complete lymph node
dissection was performed.
Additional soft tissue or in-transit metastases did not
change clinical management since multiple metastatic
sites were detected in these patients, hence systemic
treatment was initiated.
Repetitive SSTR-PET
Eight patients were imaged prior and after chemothera-
peutic treatment. Four patients showed no response,Table 2 Patient- and lesion-based analysis of SSTR-PET and C
Metastatic sites A) Patient-based assessment
SSTR-PET CT SSTR-PET sensitivity/spe
Lymph node 8 11 73%/ 92%/ 8
Lung 0 2 0%/ 100%/ 9
Pleura 1 2 50%/ 100%/
Pancreas 1 1 n/a
Bone 5 2 100%/ 83%/
Soft tissue 5 3 67%/ 90%/ 8
Liver 0 5 0%/ 100%/ 8
(A) Patient-based and (B) lesion-based analysis of SSTR-PET and CT results regardingneither by SSTR-PET nor by CT (no. 11, 15, 20, and 23).
In the remainder, a minor response according to
RECIST 1.1 or EORTC PET-criteria [26,27] was indi-
cated by both modalities. Patient no. 14 displayed dimin-
ished 68Ga-DOTATOC uptakes in the lymph node and
bone after initiation of treatment, which is indicative of
regression of the disease. In patient no. 16, a mixed re-
sponse was observed with morphologically smaller, SSTR-
PET-negative nodal but progressive pancreatic and new
cerebral SSTR-PET-positive lesions. Patient no. 21 had a
mixed response with partial remission of liver metastases
and progression of lymph node metastases identified by
both SSTR-PET and CT. Patient no. 22 showed reduction of
cutaneous satellite, and stable nodal as well as bone metasta-
ses (Figure 3). However, this short-term response was
followed by progression of all metastatic sites and develop-
ment of new cerebral metastases indicated by SSTR-PET.
Of interest, SSTR-PET identified brain metastases duringT
B) Lesion-based assessment
cificity/accuracy SSTR-PET CT SSTR-PET sensitivity
3% 62 105 59%
5% 0 6 0%
95% 1 2 50%
1 1 n/a
85% 35 20 100%
6% 8 2 100%
0% 0 33 0%
detection of lymph node and distant metastases from Merkel cell carcinoma.
Figure 2 Typical example of SSTR-positive metastases visualized by SSTR-PET. Example of SSTR-positive MCC metastases which were displayed
by SSTR-PET imaging. Corresponding CT sections are shown below the transaxial PET views. Whereas lymph node metastases can be visualized with
comparable sensitivity (arrows, A, B, E, F), SSTR-PET is more sensitive for detecting bone and brain metastases as compared to CT (C, D, I, J). On the
other hand, lung and liver metastases (arrows, E, F) are detected with lower sensitivity by SSTR-PET.
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lective, i.e. 20% of the stage IV patients; in one of them,
radiotherapy for brain metastases was performed.
Discussion
In this retrospective study, we have demonstrated that
tumor staging using specific imaging of SSTR expression
by PET is feasible and provides additional diagnostic in-
formation. All primary tumors were visualized with focal
uptake of the radiotracer, indicating that SSTR-PET
could be used for tumor localization in patients with un-
known primary.
SSTR-PET showed higher sensitivity for detection of
bone metastases as compared to CT, which is consistent
with findings in other neuroendocrine cancers [28]. Not-
ably, diagnosis of bone metastases provided a rationaleFigure 3 Repetitive SSTR-PET imaging for assessment of treatment
imaging. Patient no. 22 presented with a large primary tumor with satellite
uptake (B, C). After combined radio-chemotherapy including liposomal d
SSTR-PET (E, F).for initiation of bisphosphonate treatment in those three
patients. Interestingly, two patients of our cohort were
diagnosed with cerebral metastases based on SSTR-PET.
A rate of 8% in the total cohort, i.e. 20% in stage IV pa-
tients, is much higher than expected from previous obser-
vations that reported central nervous system involvement
to be a very rare event in MCC. Thus, SSTR-PET appears
as a highly sensitive means to detect cerebral metastases
of MCC that may have been under-diagnosed previously
[29] and SSTR-PET is superior to FDG-PET in this regard
[14]. SSTR-PET was superior to CT regarding detection
of soft tissue metastases which could also have further im-
pact on the therapeutic decision making process. Overall,
patient management was directly changed in 13% of cases.
In contrast, SSTR-PET turned out to be significantly
inferior to CT in terms of imaging liver and lungresponse. Response to therapy assessed using repetitive SSTR-PET
metastases (A). The primary tumor showed increased 68Ga-DOTATOC
oxorubicin (D), SSTR-expression was no longer detectable by
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take in the liver. With respect to the lung, pulmonary me-
tastases from MCC are generally small and motion
artifacts due to breathing negatively interfere with lesion
detection by PET. Detection of cutaneous metastases de-
pends on lesion size. In the present series, lesions had to
be at least 5 mm to be visualized with SSTR-PET. How-
ever, several skin metastases did not show increased tracer
uptake despite a size > 15 mm. A similar result has
been recently described for gamma camera-based imaging
using 111In-octreotide. With this imaging approach none of
14 cutaneous metastases were visualized in 2 patients [30].
Lymphatic metastases are frequent in MCC and se-
verely impact prognosis [5]. However, MCC affects the
elderly and is frequently localized in the head-and-neck
region, thus both SLNB and possible radical lymphade-
nectomy are associated with an increased surgery risk.
In our series, SSTR-PET was true negative in 6 SLN-
negative patients and true positive in one SLN-positive
patient but failed to demonstrate a 5 mm iliac lymph
node metastasis in a patient who underwent complete
lymph node dissection. Moreover, since neither SSTR-
nor FDG-PET/CT consistently detects nodal MCC micro-
metastases, these techniques are not intended to replace
the sentinel lymph node biopsy [8,13,15]. However, if
SSTR-PET detects unapparent lymph node metastases, as
e.g. in patient no. 15, the patient can directly undergo
complete lymphadenectomy, i.e. SLNB can be spared.
SSTR-PET may have higher diagnostic performance than
FDG-PET in MCC as pointed out in a recent case report
[24]. In a retrospective analysis, FDG-PET/(CT) has been
shown to be a useful tool in management of MCC and
may lead to upstaging of 16% of patients [14]. A head-to-Figure 4 Proposed staging algorithm for MCC. SSTR-PET/CT should b
inoperable stage III and stage IV disease. SSTR-PET/CT should be perfor
comparing DOTATOC/TATE-PET/CT versus FDG-PET/CT. **SSTR-targeted rad
studies are needed.head comparison of both imaging approaches (SSTR ex-
pression vs. FDG metabolism) warrants an interesting tool
for further research to gain deeper knowledge of tumor
biology. However, SSTR-PET is superior to FDG-PET for
detection of cerebral metastases of MCC and only SSTR-
PET harbors the possibility of a theranostic approach
towards the disease by combining diagnostic and thera-
peutic properties. Based on these notions, we propose
a staging algorithm, which includes SSTR-PET/CT
(Figure 4). Current therapy regimens for metastatic
MCC have a limited impact on the overall survival
[31]. Recently, treatment with somatostatin analogs
has been reported for both MCC and NET [32-36]. In
NETs, retention of DOTATOC, as measured by calcu-
lation of SUVmean or SUVmax, is usually at least 2-fold
higher as compared to a reference segment in the liver.
MCC lesions in our cohort showed markedly lower
tracer retention of DOTATOC/-TATE. This fact indi-
cates that response rates to targeted radionuclide ther-
apy (i.e., 90Y-DOTATOC or 177Lu-DOTATATE) may
be inferior, however, MCC is a very radiosensitive tumor
and therefore, therapy with radio-labeled somatostatin an-
alogs might nevertheless be considered in an otherwise
limited therapeutic scenario.
One of the limitations of our study is immanent to the
orphan disease status of MCC: it comprises a limited
number of patients; nevertheless, to the best of our
knowledge, this is the largest cohort of MCC patients
imaged by SSTR-PET to date. Other limitations are also
related to the low incidence of MCC: The SSTR-PETs
were carried out over a period of 3 years; over this
period substantial improvements of SSTR-PET technolo-
gies were introduced. Thus, the majority of patients weree considered prior to major surgery for stage III disease and for
med prior to radiopeptide therapy. *Further clinical trials are required
iation therapy is an experimental treatment for MCC. Further clinical
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tients were imaged by PET/CT. Thus, it can be assumed
that implementation of integrated PET/CT scanners pro-
viding enhanced image quality will facilitate detection of
smaller lesions. An example demonstrating improved
image quality and sensitivity of PET/CT devices as com-
pared to a PET only device is shown in the Additional
file 1: Figure S1. Similarly, the possible benefits of 68Ga-
DOTATATE over 68Ga-DOTATOC had been realized.
However, since we could demonstrate the advantage of
SSTR-PET in combination with contrast-enhanced CT
using older technologies for correct staging of MCC, it
can be envisaged that these benefits are even better with
improved SSTR-PET techniques.
Conclusion
This study highlights the role of molecular imaging of
SSTR expression in MCC. The advantage of SSTR-PET
is based on an improved visualization of bone, soft tissue
and brain metastases, whereas limitations relate to an in-
sufficient detection of lung and liver metastases. There-
fore, in MCC, SSTR-PET should be always performed in
combination with contrast-enhanced CT; indeed, such
an approach resulted in a change of patient management
in 13% of cases. Furthermore, focally increased tracer up-
take suggests treatment of MCC using β-emitter-labeled
SSTR analogs such as 90Y- or 177Lu-DOTATATE as a
therapeutic option.
Additional file
Additional file 1: Figure S1. Improved sensitivity by integrated PET/CT.
Example of one patient who received both PET only and contrast-enhanced
CT scan (A-C) as well as integrated PET/CT imaging six months later (D-F). A
small left-sided supraclavicular lymph node (A + D) was depicted as lymph
node metastasis by integrated PET/CT indicating focal SSTR expression of the
metastatic node (D: fused PET/CT image, E/F: PET).
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